Human Biosynthetic Insulin - Current Status and Outlook by 2015

Human biosynthetic insulin derived from E. coli or yeast has virtually replaced insulin from bovine and procine pancreas. In this extensive survey the production process for recombinant insulin is estimated for E. coli and yeast, comprising :

• cost of insulin precursor
• cost for bioactivation and purification of the precursor to insulin